Pacira BioSciences, Inc. (PCRX)
PCRX moved a median of -0.04% 30 minutes after news, and +0.17% by the close. How PCRX actually reacts to news — the realized, point-in-time move the market made, measured across 1,143 labeled events over the last three years with zero look-ahead.
PCRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.02% | 51% | 1,138 |
| 30-min | -0.04% | 48% | 1,143 |
| 60-min | +0.11% | 52% | 1,143 |
| to close | +0.17% | 53% | 1,140 |
| Middle 50% of PCRX reactions | -0.71% to +0.85% |
|---|---|
| Median reaction (30-min) | -0.04% |
| Measured reactions | 1,143 |
Half of all Pacira BioSciences, Inc. news events land between -0.71% and +0.85% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PCRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 16 | -0.72% | 31% | -0.52% |
| Analyst downgrades | 19 | -0.04% | 47% | +1.91% |
| Coverage initiations | 14 | +0.84% | 79% | +0.56% |
| Rating reiterations | 69 | -0.27% | 38% | -0.47% |
| Price-target raises | 11 | -1.39% | 18% | -4.05% |
| Price-target cuts | 16 | +0.33% | 63% | -0.04% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how PCRX ranks against every other measured name →
That’s how PCRX usually reacts — get an email when it moves on news →Email me when PCRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PCRX's baseline. Nothing else.
Recent PCRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Pacira BioSciences, Inc. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | +0.19% | |
| PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.10% | +0.19% | |
| Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home | Press release | GlobeNewswire | +1.32% | +0.60% | |
| Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom | Press release | GlobeNewswire | -0.53% | -1.42% | |
| Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.23% | +1.01% | |
| Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.86% | -2.53% | |
| Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases | Press release | GlobeNewswire | +0.85% | +2.73% | |
| Form 10-Q Pacira BioSciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.88% | -4.57% | |
| Form 8-K Pacira BioSciences, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -2.88% | -4.57% | |
| Form S-8 Pacira BioSciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.88% | -4.57% | |
| Pacira BioSciences Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -2.88% | -4.57% | |
| Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce | Press release | GlobeNewswire | +0.43% | +0.11% | |
| Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process | Press release | GlobeNewswire | -0.73% | +1.30% | |
| Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026 | Press release | GlobeNewswire | -0.74% | -0.58% | |
| Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.62% | -1.12% | |
| Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL® | Press release | GlobeNewswire | -0.19% | -2.80% | |
| Form 8-K Pacira BioSciences, Inc. For: Jun 28 | SEC filing · Form 8-K | SEC EDGAR | -2.19% | -2.42% | |
| Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet | Press release | GlobeNewswire | -2.19% | -2.42% | |
| Form 8-K Pacira BioSciences, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +0.66% | -2.42% | |
| Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting | Press release | PR Newswire | +0.82% | +0.73% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.88% | -0.74% | |
| Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting | Press release | PR Newswire | +1.88% | -0.74% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.39% | -3.09% | |
| Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees | Press release | PR Newswire | -0.39% | -3.09% | |
| DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION | Press release | PR Newswire | +0.55% | -0.71% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -2.07% | -1.86% | |
| Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees | Press release | GlobeNewswire | -2.07% | -1.86% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.55% | -0.71% | |
| Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees | Press release | GlobeNewswire | +0.55% | -0.71% | |
| Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty | Press release | GlobeNewswire | +0.20% | -1.31% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.20% | -1.31% | |
| Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy | Press release | GlobeNewswire | +0.38% | +4.33% | |
| A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching | Press release | GlobeNewswire | +0.30% | -0.60% | |
| A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC | Press release | PR Newswire | -0.29% | -1.05% | |
| DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences | Press release | PR Newswire | -0.09% | +3.09% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.20% | +3.09% | |
| Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders | Press release | GlobeNewswire | -0.20% | +3.09% | |
| DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates | Press release | PR Newswire | — | +2.72% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.51% | +1.69% | |
| Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences | Press release | GlobeNewswire | +1.23% | +1.45% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.23% | +1.45% | |
| Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees | Press release | GlobeNewswire | +1.23% | +1.45% | |
| Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.21% | -3.10% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.08% | -4.90% | |
| Pacira BioSciences Mails Letter to Stockholders | Press release | GlobeNewswire | -0.08% | -4.90% | |
| Form 10-Q Pacira BioSciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.34% | -9.14% | |
| Form 8-K Pacira BioSciences, Inc. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -1.34% | -9.14% | |
| Pacira BioSciences Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -1.34% | -9.14% | |
| Form ARS Pacira BioSciences, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.79% | -0.44% | |
| Form DEFA14A Pacira BioSciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.79% | -0.44% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PCRX section they belong to.
Where else PCRX is measured.
PCRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Epizyme, Inc. (EPZM) | 1,145 | +0.04% | 51% |
| Neogen Corporation (NEOG) | 1,143 | 0.00% | 48% |
| Anthem, Inc. (ANTM) | 1,140 | -0.01% | 49% |
| EXPRESS SCRIPTS (ESRX) | 1,137 | +0.02% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Pacira BioSciences, Inc.'s median reaction calculated?
Every labeled PCRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,143 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of PCRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PCRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.